The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality
- 1.2k Downloads
The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol.
CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis.
Results and conclusions
The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.
KeywordsHydroxyethyl starch Fluid therapy Resuscitation Colloids Randomised controlled trials
- 3.Perel P, Roberts I, Pearson M (2007) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD14000567.pub14651853
- 4.Bunn F, Trivedi D, Ashraf S (2008) Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev CD001319Google Scholar
- 7.Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, German Competence Network (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139Google Scholar
- 8.Dart A, Mutter T, Ruth C, Tabak S (2010) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD14007594.pub14651852.
- 11.Jones D, McEvoy S, Merz T, Higgins A, Bellomo R, Cooper J, Hollis S, McArthur C, Myburgh J, Taylor C, Liu B, Norton R, Finfer S (2010) International albumin use: 1995–2006. Anaesth Intensive Care Med 38:266–273Google Scholar
- 12.Zarychanski R, Turgeon A, Fergusson D, Cook D, Hebert P, Bagshaw S, Monsour D, McIntyre L (2008) Renal outcomes following hydroxyethyl starch resuscitation: a meta-analysis of randomized trials. Clin Invest Med 31:S26Google Scholar
- 16.Fenger-Eriksen C, Hartig Rasmussen C, Kappel Jensen T, Anker-Moller E, Heslop J, Frokiaer J, Tonnesen E (2005) Renal effects of hypotensive anaesthesia in combination with acute normovolaemic haemodilution with hydroxyethyl starch 130/0.4 or isotonic saline. Acta Anaesthesiol Scand 49:969–974PubMedCrossRefGoogle Scholar
- 19.Antonelli M, Azoulay E, Bonten M, Chastre J, Citerio G, Conti G, De Backer D, Lemaire F, Gerlach H, Hendenstierna G, Joannidis M, Macrae D, Mancebo J, Maggiore S, Mebazaa A, Preiser J-C, Pugin J, Wernerman J, Zhang H (2010) Year in review in Intensive Care Medicine 2009: II. Neurology, cardiovascular, experimental, pharmacology and sedation, communication and teaching. Intensive Care Med 36:412–427PubMedCrossRefGoogle Scholar
- 21.Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26:1793–1800PubMedGoogle Scholar
- 24.US Food and Drug Administration (2003) Guidance for industry. Part 11. Electronic signatures—scope and applications. Available at:http://www.21cfrpart11.com/files/fda_docs/part11_final_guidanceSep2003.pdf